合并与不合并糖尿病的患者接受Roux-en-Y胃旁路术后全因及特定原因死亡风险
研究将2004年1月至2015年12月纳入的3242例Roux-en-Y胃旁路术(RYGB)患者按年龄、BMI、性别及糖尿病状态匹配非手术对照,最终分析2428例(糖尿病625例、无糖尿病1803例)。中位随访5.8年(糖尿病)与6.7年(无糖尿病)。仅在合并糖尿病患者中,RYGB与全因死亡率降低相关(校正HR 0.44,P<0.0001);无糖尿病者全因死亡率无显著改善(校正HR 0.84,P=0.37)。结论认为RYGB的全因死亡获益主要由手术时合并糖尿病的患者驱动。
要点
- 合并糖尿病的RYGB患者全因死亡率低于对照(校正HR 0.44,P<0.0001)。
- 无糖尿病的RYGB患者全因死亡率与对照无显著差异(校正HR 0.84,P=0.37)。
- 合并糖尿病者中,对照组心血管病、呼吸系统疾病及糖尿病死亡多于RYGB组。
核心结论
- RYGB的全因死亡获益主要由手术时合并糖尿病的患者驱动。
- 合并糖尿病的RYGB患者死于心血管疾病、糖尿病及呼吸系统疾病的可能性低于未行RYGB的对照。
研究设计与样本
- 研究将2004年1月至2015年12月纳入的3242例符合条件的RYGB患者,按手术时年龄、BMI、性别及糖尿病状态匹配非手术对照。
- 共识别2428例对照(糖尿病625例、无糖尿病1803例),采用Kaplan-Meier曲线与Cox回归比较全因及特定原因死亡率。
- 术后中位随访时间:合并糖尿病者5.8年,无糖尿病者6.7年。
主要发现
- 仅在手术时合并糖尿病的患者中,RYGB组全因死亡率低于对照组(校正HR 0.44;P<0.0001)。
- 无糖尿病的RYGB患者与无糖尿病对照相比,全因死亡率无显著改善(校正HR 0.84;P=0.37)。
- 合并糖尿病者中,对照组心血管疾病死亡(P=0.011)、呼吸系统疾病死亡(P=0.017)及糖尿病死亡(P=0.011)均多于RYGB组。
- 无糖尿病的RYGB患者死于癌症(P=0.0038)及呼吸系统疾病(P=0.046)的可能性低于无糖尿病对照,但死于外部原因的风险更高(P=0.012),包括故意自伤(P=0.025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study assessed all-cause and specific-cause mortality after Roux-en-Y gastric bypass (RYGB) and in matched control subjects, stratified by diabetes status. RESEARCH DESIGN AND METHODS: RYGB patients were matched by age, BMI, sex, and diabetes status at time of surgery to nonsurgical control subjects using data from the electronic health record. Kaplan-Meier curves and Cox regression were used to assess differences in all-cause and specific-cause mortality between RYGB patients and control subjects with and without diabetes. RESULTS: Of the 3,242 eligible RYGB patients enrolled from January 2004 to December 2015, control subjects were identified for 2,428 (n = 625 with diabetes and n = 1,803 without diabetes). Median postoperative follow-up was 5.8 years for patients with diabetes and 6.7 years for patients without diabetes. All-cause mortality was reduced in RYGB patients compared with control subjects only for those with diabetes at the time of surgery (adjusted hazard ratio 0.44; P < 0.0001). Mortality was not significantly improved in RYGB patients without diabetes compared with control subjects without diabetes (adjusted hazard ratio 0.84; P = 0.37). Deaths from cardiovascular diseases (P = 0.011), respiratory conditions (P = 0.017), and diabetes P = 0.011) were more frequent in control subjects with diabetes than in RYGB patients with diabetes. RYGB patients without diabetes were less likely to die of cancer (P = 0.0038) and respiratory diseases (P = 0.046) than control subjects without diabetes but were at higher risk of death from external causes (P = 0.012), including intentional self-harm (P = 0.025), than control subjects without diabetes. CONCLUSIONS: All-cause mortality benefits of RYGB are driven predominantly by patients with diabetes at the time of surgery. RYGB patients with diabetes were less likely to die of cardiovascular diseases, diabetes, and respiratory conditions than their counterparts without RYGB.
引用
- Lent MR, Benotti PN, Mirshahi T, et al. All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes. Diabetes Care. 2017. PMID: 28760742. doi:10.2337/dc17-0519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。